1,299
Views
6
CrossRef citations to date
0
Altmetric
Research Article

A sustained dual drug delivery system for proliferative vitreoretinopathy

, , , , , , & show all
Pages 1461-1473 | Received 29 Jul 2020, Accepted 04 Oct 2020, Published online: 26 Oct 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Frances Wu & Dean Eliott. (2021) Molecular Targets for Proliferative Vitreoretinopathy. Seminars in Ophthalmology 36:4, pages 218-223.
Read now

Articles from other publishers (5)

Yajian Duan, Wenyi Wu, Jing Cui, Joanne Aiko Matsubara, Andrius Kazlauskas, Gaoen Ma, Xiaorong Li & Hetian Lei. (2023) Ligand-independent activation of platelet-derived growth factor receptor β promotes vitreous-induced contraction of retinal pigment epithelial cells. BMC Ophthalmology 23:1.
Crossref
Edward F. Xie, Bingqing Xie, Urooba Nadeem, Mark D'Souza, Gonnah Reem, Dinanath Sulakhe & Dimitra Skondra. (2023) Using Advanced Bioinformatics Tools to Identify Novel Therapeutic Candidates for Proliferative Vitreoretinopathy. Translational Vision Science & Technology 12:5, pages 19.
Crossref
Kyungmin Kang, Youngjae Song, Inho Kim & Tae-Jung Kim. (2022) Therapeutic Applications of the CRISPR-Cas System. Bioengineering 9:9, pages 477.
Crossref
Xiaoyu Xu, Chang Liu, Yonghui Wang, Oliver Koivisto, Junnian Zhou, Yilai Shu & Hongbo Zhang. (2021) Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Advanced Drug Delivery Reviews 176, pages 113891.
Crossref
M. Sarparanta & A.J. Airaksinen. 2021. Porous Silicon for Biomedical Applications. Porous Silicon for Biomedical Applications 223 253 .